May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Effect of the PKC–ß inhibitor LY 379196 alone and in combination with growth factors on the proliferation of bovine choroidal vascular endothelial cells
Author Affiliations & Notes
  • G.K. Lang
    Ophthalmology, University Eye Hospital Ulm, Ulm, Germany
  • A. Baldysiak–Figiel
    Ophthalmology, University Eye Hospital Ulm, Ulm, Germany
  • G.E. Lang
    Ophthalmology, University Eye Hospital Ulm, Ulm, Germany
  • Footnotes
    Commercial Relationships  G.K. Lang, None; A. Baldysiak–Figiel, None; G.E. Lang, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1818. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.K. Lang, A. Baldysiak–Figiel, G.E. Lang; Effect of the PKC–ß inhibitor LY 379196 alone and in combination with growth factors on the proliferation of bovine choroidal vascular endothelial cells . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1818.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Age–related macular degeneration (AMD) is associated with increased expression of the growth factors VEGF, IGF–1, and bFGF, which stimulate proliferation of choroidal endothelial cells. The proliferative action of these growth factors has been attributed, at least in part, to the activation of protein kinase C–ß (PKC–ß). In this study we investigated if LY 379196, a selective inhibitor of PKC–ß, is able to inhibit the VEGF, IGF–1, and bFGF–induced proliferation of bovine choroidal microvascular endothelial cells (BCEC). Methods: BCEC were isolated using the Dynabeads–based method and cultured in ECGM–MV medium. For proliferation assays, BCEC were seeded into 96–well–plates and grown to confluency. Subsequently, the cells were incubated in serum free defined medium for 24h and treated for another 48 h with LY 379196 (0.01 – 1000 nM) or with VEGF (20 ng/ml), IGF–1 (20 ng/ml) and bFGF (10 ng/ml) alone or in combination with LY 379196 (10 nM) in the presence of [3H]–thymidine for the last 24 h. [3H]–thymidine incorporation was assessed by liquid scintillation counting. In all experiments, untreated serum free cultures were used as negative controls. Statistical analysis was performed using two–sample t–test. Results: LY 379196 inhibited the proliferation of BCEC at the concentration of 10 – 1000 nM (p<0.01), while significantly increased cell proliferation was found in the presence of LY 379196 at the concentration of 0.01 – 1 nM (p<0.01). VEGF–, IGF–1–, and bFGF–induced BCEC proliferation (p<0.0001) was inhibited by LY 379196 at the concentration of 10 nM (p<0.0001). Conclusions:Our data show that LY 379196 has a concentration–dependent modulatory effect on BCEC proliferation and is able to abolish the potent mitotic action of VEGF, IGF–1, and bFGF, which are the key growth factors involved in the onset and progression of AMD. Our results strongly argue for the importance of the PKC–ß–dependent pathway in induction of endothelial cell proliferation. Additionally, our findings point at LY 379196 as a potent antiangiogenic drug candidate in treatment of neovascular AMD.

Keywords: age–related macular degeneration • choroid: neovascularization • proliferation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×